- Home
- RDI vs GNTA Comparison
RDI vs GNTA Comparison
Compare RDI & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDI | GNTA |
|---|---|---|
| Founded | 1937 | 2014 |
| Country | United States | Italy |
| Employees | 2025 | 13 |
| Industry | Movies/Entertainment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6M | 19.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RDI | GNTA |
|---|---|---|
| Price | $1.18 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.0K | ★ 60.1K |
| Earning Date | 04-01-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.94 | $0.59 |
| 52 Week High | $1.65 | $10.00 |
Technical Indicators
Market Signals| Indicator | RDI | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 63.57 | 31.00 |
| Support Level | $0.98 | N/A |
| Resistance Level | $1.48 | $1.70 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 95.29 | 21.27 |
Price Performance
Historical ComparisonAbout RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.